Posted by Michael Wonder on 24 Jul 2019
ICER releases draft evidence report on additive cardiovascular disease therapies
24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of icosapent ethyl (Vascepa, Amarin Pharma) and rivaroxaban (Xarelto, Janssen Pharmaceuticals), additive cardiovascular disease therapies.
This draft report will be open to public comment until 5pm ET on 20 August 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on 12 September 2019. The Evidence Report will be subject to deliberation during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees, on 26 September 2019.
